Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1996;87:747-750
© 1996 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sutton, G
Right arrow Articles by Rosenshein, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sutton, G
Right arrow Articles by Rosenshein, N

Articles

Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group

G Sutton, JA Blessing, R Park, PJ DiSaia, and N Rosenshein

OBJECTIVE: To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy. METHODS: In a prospective, multi-institutional phase II study conducted by the Gynecology Oncology Group, the starting dose of ifosfamide was 1.5 g/m2 given daily intravenously (i.v.) for 5 days (reduced to 1.2 g/m2 daily in patients who had previously received radiotherapy). Mesna (2 mercaptoethane sodium sulfonate) was given i.v. immediately and at 4 and 8 hours after the administration of ifosfamide. Each dose of mesna was 20% of the total daily dose of ifosfamide. Patients were treated every 3 weeks if blood counts permitted. Therapy was discontinued if there was progression of the cancer or unacceptable toxicity. RESULTS: Twenty-two patients were entered into this study. One was excluded from analysis because of the wrong histologic type, leaving 21 evaluable for response and toxicity. Gynecologic Oncology Group grade 3 or 4 granulocytopenia occurred in four patients (19%), and one patient each experienced Gynecologic Oncology Group grade 4 anemia and genitourinary toxicity. Three patients experienced complete tumor responses and four had partial responses, for an overall response rate of 33.3%. CONCLUSION: Ifosfamide is active in the therapy of women with chemotherapy-naive metastatic or recurrent endometrial stromal sarcomas.


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Leyvraz, M. Zweifel, G. Jundt, A. Lissoni, T. Cerny, C. Sessa, M. Fey, D. Dietrich, H. P. Honegger, and For the Swiss Group for Clinical Cancer Research (
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Ann. Onc., April 1, 2006; 17(4): 646 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Ota, K. Shinagawa, H. Ueoka, S. Tada, M. Tabata, S. Hamazaki, E. Kondo, K. Kiura, T. Mannami, T. Shibayama, et al.
Spontaneous Regression of Metastatic Endometrial Stromal Sarcoma
Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 71 - 74.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. C. Blobe, M. Mantel, M. Janicek, and G. D. Demetri
Two Patients With Sarcoma
J. Clin. Oncol., June 11, 2000; 18(11): 2343 - 2344.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Obstetricians and Gynecologists.